Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Yuviwel Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Yuviwel (navepegritide) Coverage Policy

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization for Yuviwel (navepegritide) in pediatric patients with achondroplasia. Coverage applies to patients who meet age, open-epiphysis, diagnosis, clinical-response, and concomitant-therapy requirements.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyYuviwel (navepegritide) Coverage Policy
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document a positive clinical response for reauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    Reauthorization criteria now require the patient to be younger than 18 years of age.

    ≥2 and <18Initial authorization age range
    12 monthsAuthorization duration
    <18Reauthorization age
    Open epiphysesSkeletal maturity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Achondroplasia
    Covered diagnosis
    AcceleratedApproval basis

    Coverage Criteria

    Initial Authorization

    Covered when ALL of the following are met for initial authorization.

    Initial authorization

    • Diagnosis: Patient has a diagnosis of achondroplasia.
    • Age: Patient is at least 2 years of age and younger than 18 years of age.≥2 years and <18 years
    • Skeletal maturity: Patient has open epiphyses.Open epiphyses present
    • No concomitant CNP analog: Yuviwel will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Voxzogo (vosoritide).No combination use

    Reauthorization

    Covered when ALL of the following are met for reauthorization.

    • Clinical response: There is documentation of a positive clinical response to Yuviwel therapy.Positive clinical response documented
    • Age: Patient is younger than 18 years of age.<18 years
    • Skeletal maturity: Patient has open epiphyses.Open epiphyses present
    • No concomitant CNP analog:

    Combination therapy is excluded: Yuviwel (navepegritide) must not be used with another C-type natriuretic peptide (CNP) analog, including Voxzogo (vosoritide).

    Provider Actions

    Prior Authorization

    Yuviwel Prior Authorization — Initial Approval

    Prior authorization is required for Yuviwel. Initial authorization will be issued for 12 months only when all listed clinical criteria are met.

    • Diagnosis of achondroplasia.
    • Patient is ≥ 2 years of age and < 18 years of age.
    • Presence of open epiphyses.
    • Yuviwel will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Voxzogo (vosoritide).
    • Initial authorization duration: 12 months.
    Documentation Required

    Clinical Response Documentation Required

    For reauthorization, document a positive clinical response to Yuviwel therapy in the patient’s clinical record.

    Background

    Yuviwel (navepegritide) is a C-type natriuretic peptide analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia and open epiphyses. The indication received accelerated approval based on improvement in annualized growth velocity; continued approval may depend on confirmation of clinical benefit in confirmatory trials.

    Initial Therapy Criteria

    Yuviwel Initial Authorization

    Initial therapy is covered when ALL of the following are met.

    Initial authorization

    • Diagnosis: Patient has a diagnosis of achondroplasia.
    • Age: Patient is at least 2 years of age and younger than 18 years of age.≥2 years and <18 years
    • Open epiphyses: Patient has open epiphyses.Open epiphyses present

    Continuation Criteria

    Yuviwel Reauthorization

    Reauthorization is covered when ALL of the following are met.

    Reauthorization

    • Positive clinical response: Documentation of a positive clinical response to Yuviwel therapy is provided.Positive clinical response documented
    • Age: Patient is younger than 18 years of age.<18 years
    • Open epiphyses: Patient has open epiphyses.Open epiphyses present
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyYuviwel (navepegritide) Coverage Policy
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document a positive clinical response for reauthorization.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundInitial Therapy CriteriaContinuation Criteria
    Yuviwel will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Voxzogo (vosoritide).
    No combination use
    • Positive clinical response documentation is required for continued authorization.
    Denial Risk

    Initial Authorization Criteria Not Met

    Initial authorization will be denied if any required initial authorization condition is not met.

    • No documented diagnosis of achondroplasia.
    • Patient is younger than 2 years of age or 18 years of age or older.
    • Epiphyses are not open.
    • Yuviwel will be used in combination with another CNP analog, such as Voxzogo (vosoritide).
    Denial Risk

    Reauthorization Criteria Not Met

    Reauthorization will be denied if any required reauthorization condition is not met.

    • Positive clinical response to Yuviwel therapy is not documented.
    • Patient is 18 years of age or older.
    • Epiphyses are not open.
    • Yuviwel will be used in combination with another CNP analog, such as Voxzogo (vosoritide).
    No combination therapy: Yuviwel will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Voxzogo (vosoritide).No combination use
  1. No combination therapy: Yuviwel will not be used in combination with another C-type natriuretic peptide (CNP) analog, such as Voxzogo (vosoritide).No combination use